MEDICARE Rx BENEFIT WOULD ADD $16 BIL. IN SALES FOR BRANDNAME MANUFACTURERS IN FIRST FIVE YEARS, HHS PROJECTS; NET GAIN FOR U.S. DRUG FIRMS ESTIMATED AT $2.4 BIL.
President Clinton's proposed Medicare drug benefit would add $ 16 bil. in revenues net of rebates to brandname manufacturers in the first five years, HHS Assistant Secretary for Health Philip Lee, MD, told a Feb. 8 House Energy & Commerce/Health Subcommittee hearing.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth